Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03875313
Recruitment Status : Terminated (Slow Enrollment)
First Posted : March 14, 2019
Last Update Posted : August 18, 2021
Information provided by (Responsible Party):
Calithera Biosciences, Inc

No Study Results Posted on for this Study
Recruitment Status : Terminated
Actual Primary Completion Date : July 29, 2020
Actual Study Completion Date : July 29, 2020
Submission Cycle Results Submitted to Results Returned after Quality Control Review
1 January 24, 2022